CL2020002621A1 - Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso - Google Patents

Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso

Info

Publication number
CL2020002621A1
CL2020002621A1 CL2020002621A CL2020002621A CL2020002621A1 CL 2020002621 A1 CL2020002621 A1 CL 2020002621A1 CL 2020002621 A CL2020002621 A CL 2020002621A CL 2020002621 A CL2020002621 A CL 2020002621A CL 2020002621 A1 CL2020002621 A1 CL 2020002621A1
Authority
CL
Chile
Prior art keywords
fusion protein
recombinant fusion
nrg
methods
protein compositions
Prior art date
Application number
CL2020002621A
Other languages
English (en)
Inventor
John Li
Shengwei Li
Dixiang Luo
Yiran Wu
Ming Zhou
Xiaolei Zhuang
Liang Hua
Pengyi Luo
Yang Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2020002621A1 publication Critical patent/CL2020002621A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)

Abstract

La presente invención hace referencia a una proteína de fusión recombinante que comprende un fragmento de neuregulina-1 (NRG-1) de proteína cardioprotectora fusionada a una estructura de anticuerpo monoclonal (mAb) y a un método para el tratamiento de una enfermedad o afección en un sujeto que lo necesita que comprende la administración de una cantidad terapéuticamente eficaz de la proteína de fusión recombinante o la composición farmacéutica que comprende la proteína de fusión recombinante descrita en la presente.
CL2020002621A 2018-04-11 2020-10-09 Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso CL2020002621A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862656246P 2018-04-11 2018-04-11

Publications (1)

Publication Number Publication Date
CL2020002621A1 true CL2020002621A1 (es) 2021-06-11

Family

ID=66484143

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002621A CL2020002621A1 (es) 2018-04-11 2020-10-09 Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso

Country Status (21)

Country Link
US (3) US11046741B2 (es)
EP (2) EP3774859B1 (es)
JP (2) JP2021535727A (es)
KR (1) KR20210022542A (es)
CN (1) CN113166218A (es)
AU (2) AU2019252262B2 (es)
BR (1) BR112020020646A2 (es)
CA (1) CA3096420A1 (es)
CL (1) CL2020002621A1 (es)
CO (1) CO2020012621A2 (es)
DK (1) DK3774859T3 (es)
EA (1) EA202092458A1 (es)
FI (1) FI3774859T3 (es)
IL (1) IL277790A (es)
MX (1) MX2020010740A (es)
PE (1) PE20210111A1 (es)
PH (1) PH12020551648A1 (es)
PT (1) PT3774859T (es)
SG (1) SG11202009831UA (es)
TW (1) TWI834654B (es)
WO (1) WO2019200033A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210022542A (ko) 2018-04-11 2021-03-03 샐러브리스 바이오테라퓨틱스, 인크. 인간 뉴레귤린-1(nrg-1) 재조합 융합 단백질 조성물 및 이의 사용 방법
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
JP2022547335A (ja) * 2019-09-16 2022-11-11 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 組換えヒトニューレグリン誘導体及びその使用
TW202400217A (zh) * 2022-03-15 2024-01-01 美商信立泰生物醫藥公司 用神經調節蛋白－１融合蛋白治療纖維化及心律不整的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
JP4955548B2 (ja) 2004-07-09 2012-06-20 ウェイン・ステイト・ユニバーシティ 標的化のためのＥｒｂＢ４細胞外ドメインおよびニューレグリンヘパリン結合ドメインを有するハイブリッドタンパク質
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP2011500703A (ja) 2007-10-16 2011-01-06 シンフォジェン アクティーゼルスカブ 最適化されたｈｅｒ１及びｈｅｒ３多量体を含む組成物、及びそれらの使用
AU2009223784A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
TW201014602A (en) * 2008-07-08 2010-04-16 Abbott Lab Prostaglandin E2 binding proteins and uses thereof
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
CA2775573A1 (en) * 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
EP2555788B1 (en) 2010-03-24 2017-10-11 Massachusetts Institute of Technology NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY.
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP3066124B1 (en) * 2013-11-07 2021-01-06 INSERM - Institut National de la Santé et de la Recherche Médicale Anticorps allosteriques de la neureguline, dirigés contre her3
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
KR102351755B1 (ko) 2014-04-10 2022-01-14 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
US10526416B2 (en) * 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
MX2018009581A (es) 2016-02-06 2019-05-06 Epimab Biotherapeutics Inc Inmunoglobulina con fabs en tandem y sus usos.
MX2019002664A (es) 2016-09-15 2019-09-26 Univ Stuttgart Proteina de union a antigeno contra her3.
KR20210022542A (ko) 2018-04-11 2021-03-03 샐러브리스 바이오테라퓨틱스, 인크. 인간 뉴레귤린-1(nrg-1) 재조합 융합 단백질 조성물 및 이의 사용 방법

Also Published As

Publication number Publication date
EP3774859B1 (en) 2024-03-13
DK3774859T3 (da) 2024-05-27
EP4361177A2 (en) 2024-05-01
PE20210111A1 (es) 2021-01-19
US20210347841A1 (en) 2021-11-11
AU2023285793A1 (en) 2024-01-18
EP3774859A1 (en) 2021-02-17
JP2021535727A (ja) 2021-12-23
TWI834654B (zh) 2024-03-11
AU2019252262B2 (en) 2023-10-05
FI3774859T3 (fi) 2024-05-24
MX2020010740A (es) 2021-01-20
US20200010522A1 (en) 2020-01-09
CO2020012621A2 (es) 2020-12-21
AU2019252262A1 (en) 2020-10-22
JP2023134436A (ja) 2023-09-27
EA202092458A1 (ru) 2021-02-08
WO2019200033A1 (en) 2019-10-17
PT3774859T (pt) 2024-05-27
TW201945389A (zh) 2019-12-01
KR20210022542A (ko) 2021-03-03
US11046741B2 (en) 2021-06-29
BR112020020646A2 (pt) 2021-02-23
CA3096420A1 (en) 2019-10-17
PH12020551648A1 (en) 2021-07-26
IL277790A (en) 2020-11-30
US20230322877A1 (en) 2023-10-12
US11718652B2 (en) 2023-08-08
SG11202009831UA (en) 2020-11-27
CN113166218A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
CL2020002621A1 (es) Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso
AR106991A1 (es) Anticuerpos neutralizantes del virus de inmunodeficiencia humana
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
JP2020109110A (ja) 骨形成不全症の処置方法
PE20091449A1 (es) Proteinas de union a antigenos
CL2008002668A1 (es) Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp.
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
RU2013105769A (ru) Биологические материалы и их применение
BR112022009273A2 (pt) Imunoglobulinas modificadas para direcionar depósitos amiloides
IL259940B2 (en) A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
HRP20231650T1 (hr) Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka
CL2022000230A1 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
BR112021020777A2 (pt) Vacina de subunidade do csfv
WO2017191327A3 (en) Her-2 binding antibodies
AU2018281871A1 (en) Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
PE20190633A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
TW202426470A (zh) 人神經調節蛋白－１（ｎｒｇ－１）重組融合蛋白組成物及其使用方法
AR122237A1 (es) Anticuerpos anti-sortilina y métodos para su uso